Citation Impact
Citing Papers
RIP3, an Energy Metabolism Regulator That Switches TNF-Induced Cell Death from Apoptosis to Necrosis
2009 StandoutScience
Interferons and Apoptosis
2003
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
2009
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy
2005
Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia
2004
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
2015
Cancer statistics, 2020
2020 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines
2005
NMR structure and mutagenesis of the FADD (Mort1) death-effector domain
1998 Nature
In TNF-stimulated Cells, RIPK1 Promotes Cell Survival by Stabilizing TRAF2 and cIAP1, which Limits Induction of Non-canonical NF-κB and Activation of Caspase-8
2011
Breast cancer
2016 Standout
The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys
2004 StandoutNature
Necroptosis and its role in inflammation
2015 StandoutNature
Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α
2009 Standout
Regulation of V2 Vasopressin Receptor Degradation by Agonist-promoted Ubiquitination
2003 StandoutNobel
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
2008
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
2006
Integrins Form an Expanding Diffusional Barrier that Coordinates Phagocytosis
2016 StandoutNobel
Roles of Fas and Fas ligand during mammary gland remodeling
2000
CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells
2009
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
2008
The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible
2016 Standout
The RING Finger of c-Cbl Mediates Desensitization of the Epidermal Growth Factor Receptor
1999
Skin Cancers after Organ Transplantation
2003 Standout
The biochemistry of apoptosis
2000 StandoutNature
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
2016
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation
2009 Standout
Inducible resistance to Fas-mediated apoptosis in B cells
2000
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Bid Mediates Apoptotic Synergy between Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and DNA Damage
2004
Epithelioid Angiosarcoma Arising in a Surgically Constructed Arteriovenous Fistula
1998
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
2010
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Role of bisphosphonates in postmenopausal women with breast cancer
2013
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
2011
Apoptosis
2002 Standout
Death and anti-death: tumour resistance to apoptosis
2002 Standout
RIPK1 Blocks Early Postnatal Lethality Mediated by Caspase-8 and RIPK3
2014
Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
2005
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Tumor Necrosis Factor-induced Nonapoptotic Cell Death Requires Receptor-interacting Protein-mediated Cellular Reactive Oxygen Species Accumulation
2004
c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment
2009
Structurally Distinct Phosphatases CD45 and CD148 Both Regulate B Cell and Macrophage Immunoreceptor Signaling
2008
Future directions of bone-targeted therapy for metastatic breast cancer
2010
Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics
2006 StandoutNobel
Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature
2011
Degradation of the Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) by the Ubiquitin-Proteasome Pathway
2000 StandoutNobel
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs
2011
NF-κB functions as a tumour promoter in inflammation-associated cancer
2004 StandoutNature
Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1
1999 StandoutNobel
The TNF and TNF Receptor Superfamilies
2001 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Cbl-mediated Ubiquitinylation Is Required for Lysosomal Sorting of Epidermal Growth Factor Receptor but Is Dispensable for Endocytosis
2003
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
2006 Standout
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
2002
Novel approaches to target the microenvironment of bone metastasis
2021
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Advances in Malignant Mesothelioma
2005 Standout
TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB
2003
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Defining CD95 as a tumor suppressor gene
2000
Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.
1999
I787 provides signals for c-Kit receptor internalization and functionality that control mast cell survival and development
2010 StandoutNobel
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
2012 Standout
Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.
2001
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
2002
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
2000
Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening
2014
Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications
2008 Standout
Clonal B cells in patients with hepatitis C virus–associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
2011 StandoutNobel
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Tumor Immunity in Perforin-Deficient Mice: A Role for CD95 (Fas/APO-1)
2000
Nanoparticles in Photodynamic Therapy
2015 Standout
Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer
2020
Regulation of apoptosis by the circadian clock through NF-κB signaling
2011 StandoutNobel
A Tale of Two Cbls: Interplay of c-Cbl and Cbl-b in Epidermal Growth Factor Receptor Downregulation
2008
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation
2015
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
2002 StandoutNobel
Combining TRAIL with PI3 Kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
2013
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl)
2004
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
The Phosphoinositide 3-Kinase Pathway
2002 StandoutScience
Works of Maccon Keane being referenced
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
2001
cbl-3: a new mammalian cbl family protein
1999
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
2013
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer
2011
Imaging of the gastrointestinal complications of systemic chemotherapy
2009
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
2008
Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines
2000
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
2014
cbl-b Inhibits EGF-Receptor-Induced Apoptosis by Enhancing Ubiquitination and Degradation of Activated Receptors
1999
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
2010
cbl-b inhibits epidermal growth factor receptor signaling
1999
Angiosarcoma Arising from a Defunctionalized Arteriovenous Fistula
1993
The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells.
1996
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
1999
Fas expression and function in normal and malignant breast cell lines.
1996
The Death Domain Kinase RIP Is Essential for TRAIL (Apo2L)-Induced Activation of IκB Kinase and c-Jun N-Terminal Kinase
2000
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.
2018
Abstract S4-5: Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04)
2010